A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
Approved for marketing
Pfizer
2004-09-01
The purpose of this study is to permit access to SU011248 for treatment use by patients with
GIST given the following conditions: a) patients undergo screening, but are not eligible for
participation in ongoing clinical studies such as A6181004; AND b) patients have GIST which
standard treatments have not been able to control with acceptable toxicity AND c) patients
have the potential to derive clinical benefit from treatment with SU011248.
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Approved for marketing
Pfizer
2005-07-01
The primary objective of this protocol is to provide access to SU011248 treatment for
patients with metastatic RCC who are ineligible for participation in ongoing SU011248
clinical studies and have the potential to derive clinical benefit from treatment with
SU011248 based on the judgment of the investigator.
Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
Completed
Pfizer
Phase 1/Phase 2
2005-10-01
This is a multi-center, open-label, Phase 1/2 study of SU011248 (sunitinib malate, SUTENT) in
combination with docetaxel and prednisone for the first-line treatment of metastatic
hormone-refractory prostate cancer (mHRPC).
Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
Completed
Pfizer
Phase 2
2006-01-01
The purpose of this study is to compare progression free survival for SU011248 [sutent
(sunitinib malate)] versus standard of care therapy in patients with previously treated,
advanced, triple receptor negative (ER, PR, HER2) locally recurrent or metastatic breast
cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
